MedTrace Logo

The Effect of Effervescent Alendronate on Bone Turnover

NCT05325515 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-02-08

No results posted yet for this study

Summary

64 postmenopausal women are randomized to treatment with either effervescent and buffered alendronate or conventional alendronate -both 70mg weekly for 16 weeks to see if bone turnover is suppressed to the same extent as in the conventional formulation with the effervescent form.

Conditions

  • Osteopenia or Osteoporosis

Interventions

DRUG

Conventional alendronate

Conventional alendronate 70mg weekly

DRUG

Effervescent and buffered alendronate

Effervescent and buffered alendronate 70mg weekly

Sponsors & Collaborators

  • Aarhus University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-09-01
Completion
2022-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05325515 on ClinicalTrials.gov